Mouse IgG1 Isotype Control [Clone HKSP] — Purified in vivo GOLD™ Functional Grade
Antibody DetailsProduct DetailsHost Species Mouse Recommended Dilution Buffer Product Concentration ≥ 5.0 mg/ml Endotoxin Level < 1.0 EU/mg as determined by the LAL method Purity ≥95% monomer by analytical SEC ⋅ >95% by SDS Page Formulation This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration. Product Preparation Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates. Storage and Handling Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles. Country of Origin USA Shipping Next Day 2-8°C Working Concentration This Mouse IgG isotype control antibody should be used at the same concentration as the primary antibody. RRIDAB_2737545 Applications and Recommended Usage? Quality Tested by Leinco FC This isotype control antibody should be used at the same concentration as the primary antibody. Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionSpecificity This Mouse IgG1 isotype control antibody (Anti-BTV) has been tested against selected species' cells and tissues to assure minimal cross reactivity. Research Area Cell Biology Leinco Antibody AdvisorPowered by AI: AI is experimental and still learning how to provide the best assistance. It may occasionally generate incorrect or incomplete responses. Please do not rely solely on its recommendations when making purchasing decisions or designing experiments. Clone HKSP is primarily used as a Mouse IgG1 Isotype Control in in vivo mouse studies. Its main application is as a negative control to distinguish specific effects of a test antibody from non-specific effects related to antibody isotype, Fc receptor binding, or other background interactions. This means it is commonly used to provide a baseline for evaluating the effects of experimental antibodies or treatments in mice, ensuring that any observed effects are due to the specific action of the test antibody rather than irrelevant factors like isotype or Fc receptor interactions. Here are some common applications of clone HKSP in mice:
In summary, clone HKSP is crucial for ensuring the validity and specificity of in vivo antibody studies in mice. Based on the search results, HKSP (Heat-Killed Streptococcus pneumoniae) is primarily used in immunological research to study immune responses, particularly the polysaccharide antibody response. However, the search results do not provide extensive information about other antibodies or proteins commonly paired with HKSP in scientific literature. The main focus in HKSP research involves studying the antibody response itself rather than using HKSP in combination with other specific antibodies. The studies examine how the immune system responds to HKSP vaccination by measuring various antibody isotypes (IgM, IgG2b, IgG3) and antibody-secreting cells (ASC) in different tissues like the spleen and bone marrow. One relevant finding is that noncognate T cell help was required for an optimal polysaccharide-capsular (PC) response after HKSP immunization. The research also investigated the response to PspA (Pneumococcal surface protein A), which is a T-dependent antigen, alongside the PC response when using HKSP. It's worth noting that there appears to be some confusion in the search results, as some sources mention KSP (Kinesin Spindle Protein) inhibitors used in antibody-drug conjugates, which is an entirely different research area unrelated to HKSP immunology studies. These KSP-related findings involve cancer therapeutics and should not be conflated with HKSP immune response research. The available information suggests that HKSP research primarily focuses on characterizing the immune response itself rather than combining it with other antibodies or proteins for detection or therapeutic purposes. Clone HKSP is referenced in scientific literature primarily as a mouse IgG1 isotype control antibody, most notably used for experimental controls in immunological assays such as flow cytometry and immunohistochemistry. Key findings and typical uses from scientific citations include:
Limitations in the literature:
Summary Table: Scientific Role of Clone HKSP
If you need information about functional antibodies or clones with biological or therapeutic significance, HKSP does not fit that category—it is exclusively cited as a control in experimental design. Currently, there is no standardized dosing regimen for clone HKSP across different mouse models. The available literature and dosing guides do not provide specific dosing regimens for clone HKSP, and its usage may vary significantly depending on the experimental design, mouse strain, and immune function targeted. This variability highlights the absence of consistent protocols for dosing regimens in mouse models, which can complicate data interpretation and comparison across studies. For different applications, mouse models vary widely, including variations in immunocompetence (e.g., NOD/SCID, NSG, MISTRG), age, and the purpose of the study (e.g., hematopoietic stem cell gene therapy, immuno-oncology research). These factors contribute to the diversity in experimental parameters and dosing strategies but do not provide standardized dosing regimens for specific clones like HKSP. References & Citations1. Crack, Peter J. et al. (2016) eNeuro 10.1523/ENEURO.0128-15.2016 Article Link 2. Shin, Haina et al. (2018) J Virol. 92(7): e00038-18. PubMed 3. Karki et al. (2021) Cell. 184:149–168 Journal Link 4. Ortiz et al. (2019) Cancer Cell. 35:33–45 Journal Link 5. Smyth et al. (2020) Cancer Immunol Res 8:1-12 Journal Link 6. Swaminathan, S. et al. (2020) Nat Commun 11: 2860 Journal Link 7. Karki, R. et al. (2020) Cell 184(1):149–168.e17 Journal Link 8. Tzetzo, S. L., Kramer, E. D., Mohammadpour, H., Kim, M., Rosario, S. R., Yu, H., Dolan, M., Oturkar, C. C., Morreale, B., Bogner, P. N., Stablewski, A., Benavides, F., Brackett, C. M., Ebos, J. M., Das, G. M., Opyrchal, M., Nemeth, M. J., Evans, S. S., & Abrams, S. I. (2024). Downregulation of IRF8 in alveolar macrophages by G-CSF promotes metastatic tumor progression. iScience, 109187. https://doi.org/10.1016/j.isci.2024.109187 Technical ProtocolsCertificate of Analysis |
Related Products
Formats Available
Prod No. | Description |
---|---|
I-128 | |
I-906 | |
I-907 | |
I-908 | |
I-910 | |
I-104 | |
I-536 | |
I-133 | |
I-103 | |
M1411 |
